Company Description
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy.
The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs.
It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
| Country | United States |
| Founded | 2012 |
| IPO Date | Nov 8, 2019 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 218 |
| CEO | Antony Koblish |
Contact Details
Address: 1 Great Valley Parkway, Suite 24 Malvern, Pennsylvania 19355 United States | |
| Phone | 484 320 2930 |
| Website | telabio.com |
Stock Details
| Ticker Symbol | TELA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $13.00 |
| CIK Code | 0001561921 |
| CUSIP Number | 879385100 |
| ISIN Number | US8723811084 |
| Employer ID | 45-5320061 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Roberto E. Cuca J.D. | Chief Financial Officer, Corporate Secretary and Chief Operating Officer |
| Megan Smeykal | Vice President, Corporate Controller, Chief Accounting Officer and Principal Accounting Officer |
| Paul Talmo | Chief Technology Officer |
| D. Taylor Ocasio | General Counsel and Corporate Secretary |
| Jim Hagen | Senior Vice President of Strategic Commercial Operations and Marketing |
| Jennifer Lou Armstrong | Senior Vice President of Human Resources |
| Gregory A. Firestone | Chief Business Officer |
| Michael Leonard | Senior Vice President of Technical Operations |
| Dr. Howard N. Langstein | Chief Medical Officer |
| Louisa Smith | Investor Relations Contact Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 11, 2026 | 8-K | Current Report |
| Jun 9, 2026 | SCHEDULE 13D | Filing |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 13, 2026 | 10-Q | Quarterly Report |
| May 12, 2026 | 8-K | Current Report |
| Apr 30, 2026 | ARS | Filing |
| Apr 30, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 30, 2026 | 8-K | Current Report |
| Mar 25, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |